Pharsight

1. Adhansia Xr patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10512613	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (11 years from now)
US10500162	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (11 years from now)
US10449159	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (11 years from now)
US10688060	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (11 years from now)
US10292938	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (11 years from now)
US10292939	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (11 years from now)
US10507186	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (11 years from now)
US10512612	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (11 years from now)
US10568841	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (11 years from now)
US9974752	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (11 years from now)
US10111839	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (11 years from now)
US10722473	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Nov, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-82)	Jun 28, 2024
New Product(NP)	Feb 27, 2022

Market Authorisation Date: 27 February, 2019

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
85MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
70MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
35MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
55MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
45MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
25MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued

ADHANSIA XR family patents

2. Aptensio Xr patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6419960	RHODES PHARMS	Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations	Dec, 2019 (4 years ago)
US10039719	RHODES PHARMS	Methods of treating attention deficit hyperactivity disorder	Dec, 2019 (4 years ago)
US9801823	RHODES PHARMS	Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations	Dec, 2019 (4 years ago)
US9066869	RHODES PHARMS	Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations	Dec, 2019 (4 years ago)
US10463624	RHODES PHARMS	Controlled release formulations	Dec, 2019 (4 years ago)
US7083808	RHODES PHARMS	Controlled/modified release oral methylphenidate formulations	Dec, 2019 (4 years ago)
US7438930	RHODES PHARMS	Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations	Dec, 2019 (4 years ago)
US8580310	RHODES PHARMS	Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations	Dec, 2019 (4 years ago)
US7247318	RHODES PHARMS	Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations	Dec, 2019 (4 years ago)
US7083808 (Pediatric)	RHODES PHARMS	Controlled/modified release oral methylphenidate formulations	Jun, 2020 (3 years ago)
US7438930 (Pediatric)	RHODES PHARMS	Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations	Jun, 2020 (3 years ago)
US8580310 (Pediatric)	RHODES PHARMS	Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations	Jun, 2020 (3 years ago)
US9801823 (Pediatric)	RHODES PHARMS	Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations	Jun, 2020 (3 years ago)
US9066869 (Pediatric)	RHODES PHARMS	Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations	Jun, 2020 (3 years ago)
US10039719 (Pediatric)	RHODES PHARMS	Methods of treating attention deficit hyperactivity disorder	Jun, 2020 (3 years ago)
US7247318 (Pediatric)	RHODES PHARMS	Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations	Jun, 2020 (3 years ago)
US6419960 (Pediatric)	RHODES PHARMS	Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations	Jun, 2020 (3 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Apr 17, 2018

Market Authorisation Date: 17 April, 2015

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
60 mg	23 Dec, 2015	1	13 Dec, 2018	16 Dec, 2019	Eligible
10 mg	24 Dec, 2015	1	13 Dec, 2018	16 Dec, 2019	Eligible
15 mg, 20 mg, 40 mg and 50 mg	28 Dec, 2015	1	13 Dec, 2018	16 Dec, 2019	Eligible
30 mg	28 Mar, 2016	1	13 Dec, 2018	16 Dec, 2019	Eligible

Strength	Dosage	Availability
30MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
15MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
20MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
10MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
60MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
50MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
40MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

APTENSIO XR family patents

3. Concerta patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9029416	JANSSEN PHARMS	Methods and devices for providing prolonged drug therapy	Jul, 2017 (6 years ago)
US9000038	JANSSEN PHARMS	Methods and devices for providing prolonged drug therapy	Jul, 2017 (6 years ago)
US6919373	JANSSEN PHARMS	Methods and devices for providing prolonged drug therapy	Jul, 2017 (6 years ago)
US8629179	JANSSEN PHARMS	Methods and devices for providing prolonged drug therapy	Jul, 2017 (6 years ago)
US8163798	JANSSEN PHARMS	Methods and devices for providing prolonged drug therapy	Jul, 2017 (6 years ago)
US6930129	JANSSEN PHARMS	Methods and devices for providing prolonged drug therapy	Jul, 2017 (6 years ago)
US9144549	JANSSEN PHARMS	Methods and devices for providing prolonged drug therapy	Jul, 2017 (6 years ago)
US8629179 (Pediatric)	JANSSEN PHARMS	Methods and devices for providing prolonged drug therapy	Jan, 2018 (6 years ago)
US6919373 (Pediatric)	JANSSEN PHARMS	Methods and devices for providing prolonged drug therapy	Jan, 2018 (6 years ago)
US9000038 (Pediatric)	JANSSEN PHARMS	Methods and devices for providing prolonged drug therapy	Jan, 2018 (6 years ago)
US6930129 (Pediatric)	JANSSEN PHARMS	Methods and devices for providing prolonged drug therapy	Jan, 2018 (6 years ago)
US8163798 (Pediatric)	JANSSEN PHARMS	Methods and devices for providing prolonged drug therapy	Jan, 2018 (6 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-88)	Nov 04, 2012

Market Authorisation Date: 01 August, 2000

Treatment: Method of treating adhd; Method of treating adhd in children 6 years of age and older and adolescents; For claims 1-4,6-14,16-24 and 26-32: method of treating adhd in children 6 years of age and older...

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
27MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
36MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
54MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
18MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

CONCERTA family patents

4. Jornay Pm patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9034902	IRONSHORE PHARMS	Methods for treatment of attention deficit hyperactivity disorder	Mar, 2032 (7 years from now)
US10617651	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (7 years from now)
US9023389	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (7 years from now)
US9283214	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (7 years from now)
US10905652	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (7 years from now)
US8927010	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (7 years from now)
US9498447	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (7 years from now)
US9603809	IRONSHORE PHARMS	Methods of treatment of attention deficit hyperactivity disorder	Mar, 2032 (7 years from now)
US8916588	IRONSHORE PHARMS	Methods for treatment of attention deficit hyperactivity disorder	Mar, 2032 (7 years from now)
US11241391	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (7 years from now)
US9028868	IRONSHORE PHARMS	Methods and compositions for treatment of attention deficit disorder	Mar, 2032 (7 years from now)
US10182995	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (7 years from now)
US11241392	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (7 years from now)
US10881618	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (7 years from now)
US10292937	IRONSHORE PHARMS	Methods of treatment of attention deficit hyperactivity disorder	Mar, 2032 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Aug 08, 2021

Market Authorisation Date: 08 August, 2018

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
100MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
60MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
80MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
20MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
40MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

JORNAY PM family patents

5. Metadate Cd patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6344215	AYTU BIOPHARMA	Methylphenidate modified release formulations	Oct, 2020 (3 years ago)

Market Authorisation Date: 27 May, 2003

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
10 mg, 20 mg and 30 mg	13 May, 2005	1	19 Jul, 2012	27 Oct, 2020	Non-Forfeiture
40 mg	15 Mar, 2007	1	19 Jul, 2012	27 Oct, 2020	Non-Forfeiture

Strength	Dosage	Availability
10MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
30MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
20MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
40MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

METADATE CD family patents

6. Methylin patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7691880	SPECGX LLC	Methylphenidate solution and associated methods of administration and production	Oct, 2024 (5 months from now)

Market Authorisation Date: 19 December, 2002

Treatment: NA

Dosage: SOLUTION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
5 mg/5 mL 10 mg/5 mL	13 Apr, 2010	1	23 Jul, 2010	07 Oct, 2024	Eligible

Strength	Dosage	Availability
10MG/5ML	SOLUTION;ORAL	Prescription
5MG/5ML	SOLUTION;ORAL	Prescription

METHYLIN family patents

7. Quillichew Er patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8202537	NEXTWAVE PHARMS	Modified release formulations containing drug-ion exchange resin complexes	Mar, 2027 (2 years from now)
US8287903	NEXTWAVE PHARMS	Orally effective methylphenidate extended release powder and aqueous suspension product	Feb, 2031 (6 years from now)
US11103494	NEXTWAVE PHARMS	Methylphenidate extended release chewable tablet	Aug, 2033 (9 years from now)
US10857143	NEXTWAVE PHARMS	Methylphenidate extended release chewable tablet	Aug, 2033 (9 years from now)
US8999386	NEXTWAVE PHARMS	Methylphenidate extended release chewable tablet	Aug, 2033 (9 years from now)
US11633389	NEXTWAVE PHARMS	Methylphenidate extended release chewable tablet	Aug, 2033 (9 years from now)
US9844544	NEXTWAVE PHARMS	Methylphenidate extended release chewable tablet	Aug, 2033 (9 years from now)
US9545399	NEXTWAVE PHARMS	Methylphenidate extended release chewable tablet	Aug, 2033 (9 years from now)
US11103495	NEXTWAVE PHARMS	Methylphenidate extended release chewable tablet	Aug, 2033 (9 years from now)
US9295642	NEXTWAVE PHARMS	Methylphenidate extended release chewable tablet	Aug, 2033 (9 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Dec 04, 2018

Market Authorisation Date: 04 December, 2015

Treatment: A method for treating a subject having adhd, said method comprising orally administering to said subject a racemic methylphenidate chewable tablet as claimed; A method of providing a subject with a th...

Dosage: TABLET, EXTENDED RELEASE, CHEWABLE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
20 mg, 30 mg and 40 mg	25 Apr, 2016	1		14 Aug, 2033

Strength	Dosage	Availability
20MG	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	Prescription
40MG	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	Prescription
30MG	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	Prescription

QUILLICHEW ER family patents

8. Quillivant Xr patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8062667	NEXTWAVE	Modified release formulations containing drug-ion exchange resin complexes	Mar, 2029 (4 years from now)
US8956649	NEXTWAVE	Orally effective methylphenidate extended release powder and aqueous suspension product	Feb, 2031 (6 years from now)
US8465765	NEXTWAVE	Orally effective methylphenidate extended release powder and aqueous suspension product	Feb, 2031 (6 years from now)
US8563033	NEXTWAVE	Orally effective methylphenidate extended release powder and aqueous suspension product	Feb, 2031 (6 years from now)
US8778390	NEXTWAVE	Orally effective methylphenidate extended release powder and aqueous suspension product	Feb, 2031 (6 years from now)
US9040083	NEXTWAVE	Orally effective methylphenidate extended release powder and aqueous suspension product	Feb, 2031 (6 years from now)
US8287903	NEXTWAVE	Orally effective methylphenidate extended release powder and aqueous suspension product	Feb, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Sep 27, 2015

Market Authorisation Date: 27 September, 2012

Treatment: Method of treating attention deficit hyperactivity disorder by administering the composition of claim 1; Treating a patient having a condition susceptible to treatment with methylphenidate, such as ad...

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
5MG/ML	FOR SUSPENSION, EXTENDED RELEASE;ORAL	Prescription

QUILLIVANT XR family patents

9. Ritalin La patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6635284	SANDOZ	Delivery of multiple doses of medications	Dec, 2015 (8 years ago)
US7431944	SANDOZ	Delivery of multiple doses of medications	Dec, 2015 (8 years ago)
US5837284	SANDOZ	Delivery of multiple doses of medications	Dec, 2015 (8 years ago)
US6228398	SANDOZ	Multiparticulate modified release composition	Nov, 2019 (4 years ago)

Market Authorisation Date: 10 April, 2004

Treatment: Treatment of attention deficit hyperactivity disorder using a dosage form which provides once-daily oral administration of a phenidate drug; Treatment of attention deficit hyperactivity disorder using...

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Pharsight

Drugs that contain Methylphenidate Hydrochloride

1. Adhansia Xr patents expiration

ADHANSIA XR family patents

2. Aptensio Xr patents expiration

APTENSIO XR family patents

3. Concerta patents expiration

CONCERTA family patents

4. Jornay Pm patents expiration

JORNAY PM family patents

5. Metadate Cd patents expiration

METADATE CD family patents

6. Methylin patents expiration

METHYLIN family patents

7. Quillichew Er patents expiration

QUILLICHEW ER family patents

8. Quillivant Xr patents expiration

QUILLIVANT XR family patents

9. Ritalin La patents expiration

RITALIN LA family patents

Related content

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
10 mg	21 May, 2007	1		01 Nov, 2019	Extinguished
20 mg, 30 mg and 40 mg	21 Aug, 2006